Ultragenyx Pharmaceutical Inc. (RARE) Form 8-K — Aug 4, 2026
Ultragenyx (NASDAQ: RARE) reported Q2 2026 total revenue of $214 million, up from $167 million in Q2 2025 and the highest quarterly revenue in the company's history. Crysvita generated $156 million and Dojolvi $27 million in the quarter. Net loss narrowed to $92 million, or $0.90 per share, from $115 million, or $1.17 per share, a year earlier. The company reaffirmed full-year 2026 revenue guidance of $730-760 million and said it remains on track for profitability in 2027, with 2027 R&D and SG&A expenses expected to decline at least 15% versus 2025.
Key figures
- Revenue
- 214000000
- Guidance
- Reaffirmed FY2026 total revenue of $730-760 million; Crysvita $500-520 million; Dojolvi $100-110 million; combined R&D and SG&A flat to slightly down vs. 2025; 2027 combined R&D/SG&A expected to decrease at least 15%; on path to profitability in 2027
- Revenue Yoy
- 28% increase vs. $167 million in Q2 2025
- Cash Position
- 436000000
- Pdufa ux111
- 2026-09-19
- Pdufa dtx401
- 2026-08-23
- Cash dec31 2025
- 737000000
- H1 2026 revenue
- 350000000
- Q2 2025 revenue
- 167000000
- Gtx102 phase3 data
- September 2026
- Q2 2026 rd expense
- 167000000
- Q2 2026 total opex
- 289000000
- Q2 2026 sga expense
- 88000000
- Q2 stock based comp
- 34000000
- Shares used in eps q2
- 101.9 million
- H1 2026 restructuring expense
- 30000000
- Q2 2026 net cash used in operations
- 97000000
Price after filing
Close on the filing date to close N calendar days later (from $26.04). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.